Dustin Samples

Cancer Nursing Today nonprod

A recent study characterized the risk of major adverse cardiovascular events (MACE) and bleeding in patients with a history of myeloproliferative neoplasms (MPN) who experienced acute myocardial infarction (AMI).The research team, led by Orly Leiva, MD, of the New York University Grossman School of Medicine, retrospectively reviewed a cohort of patients using data from the National Inpatient Sample. Adult patients who experienced AMI between September 2015 and December 2018 who had a history of MPN were included.Patients were stratified by type of MPN: essential thrombocytopenia (ET), polycythemia vera (PV), or primary myelofibrosis (PMF). ET was used as the comparison group and contained the most patients (n=2359; PV, n=681; PMF, n=116).The primary study outcomes were inpatient MACE, arterial thrombotic events (ATE) and venous thrombosis embolisms (VTE), nonfatal cardiac arrest, and mortality. Secondary outcomes included in-hospital bleeding events requiring blood transfusion, ATE, VTE, and in-hospital mortality.To evaluate risk of MACE, ATE, VTE, and mortality, there were a number of covariables used for comparison: age, sex, race, hypertension, cancer, diabetes mellitus, coronary artery disease, prior percutaneous coronary intervention, prior VTE, history of renal failure, history of heart failure, obesity, private insurance status, Charlson comorbidity index, length of stay, ST-elevation myocardial infarction presentation, in-hospital cardiogenic shock, in-hospital ATE (mortality only), VTE (mortality only), and bleeding (mortality only).The results of the analysis showed that the patients with ET and PV who experienced AMI had similar rates of MACE, mortality, and VTE; however, patients with PV had a higher risk of ATE (but lower risk of bleeding) than those with ET. Patients with PMF had a higher risk of MACE and mortality than those with ET, but they had a lower risk of ATE, VTE, and bleeding.&ldquo;More investigation is needed in order to identify risk factors for adverse cardiovascular outcomes in patients with MPNs and improved post-AMI outcomes,&rdquo; Dr. Leiva and colleagues concluded.Leiva O, Siddiqui E, Hobbs GS, Bangalore S. Risk factors for major adverse cardiac events and bleeding in patients with myeloproliferative neoplasms admitted for myocardial infarction. Abstract #4372. Presented at the 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, Louisiana.

Acute Myocardial Infarction in Patients With MPN: What Happens Next?

Patients with MPN who had an acute myocardial infarction are analyzed for risk of additional major adverse cardiovascular events and bleeding

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe